<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02522338</url>
  </required_header>
  <id_info>
    <org_study_id>1008078</org_study_id>
    <secondary_id>2010-022272-31</secondary_id>
    <nct_id>NCT02522338</nct_id>
  </id_info>
  <brief_title>Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance</brief_title>
  <acronym>HIVOL</acronym>
  <official_title>Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystatin C, a protease inhibitor produced by most nucleated cells, is freely filtered by the&#xD;
      kidneys, and its plasma assay reflects the GFR.&#xD;
&#xD;
      Compare, in HIV patients, the predictive performance of 11 formula to estimate GFR based on&#xD;
      assay plasma cystatin C with that of the MDRD formulas.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient with a predictive performance range -30% to +30%</measure>
    <time_frame>day 0</time_frame>
    <description>for each estimator :predictive performance calculated by [(DFG estimé* - DFG mesuré par iohexol**)/DFG mesuré par iohexol]X100</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>iohexol plasma clearance</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients had received iohexol for measuring GFR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iohexol</intervention_name>
    <description>10 ml de l'iohexol (300 mgI/ml)</description>
    <arm_group_label>iohexol plasma clearance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients infected with HIV, and included in the cohort NADIS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with a known allergy&#xD;
&#xD;
          -  Patients treated with metformin&#xD;
&#xD;
          -  Patients with severe hepatic impairment defined as a TP spontaneously below 50%&#xD;
&#xD;
          -  Patients with a history of dysthyroidism&#xD;
&#xD;
          -  Patient with active neoplasia other than skin cancer&#xD;
&#xD;
          -  Degradation recent (not older than 3 months) in renal function defined as the&#xD;
             deterioration of GFR over 25%.&#xD;
&#xD;
          -  Estimated GFR less than 15 mL/min/1, 73m2&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Subjects under the protection of justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric LUCHT, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>March 9, 2016</last_update_submitted>
  <last_update_submitted_qc>March 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

